Table 3.
Main Clinical Features of Patients Used for Mucosa Molecular Analyses
| Patient (n) | Explant location (n) | Age at surgery, y (minimum–maximum) | Sex (M/F) | Treatment at time of surgery (n) |
|---|---|---|---|---|
| Control, cancer at a distance from tumor (20) | Ileum (4) | 61.8 (38–82) | 14/6 | None (19) |
| Colon (15) | Radiotherapy (1) | |||
| Rectum (1) | ||||
| CD (20) | Ileum (8) | 37.4 (17–63) | 9/11 | None (7) |
| Colon (12) | Mesalamine (1) | |||
| Rectum (0) | IS (4) | |||
| MTT + IS (1) | ||||
| Anti-TNF (6) | ||||
| Anti-TNF+IS (1) | ||||
| UC (16) | Ileum (2) | 43 (19–60) | 8/8 | None (11) |
| Colon (11) | Mesalamine (1) | |||
| Rectum (3) | IS (0) | |||
| MTT + IS (0) | ||||
| Anti-TNF (4) | ||||
| Anti-TNF+IS (0) |
CD, Crohn’s disease; IS, immunosuppressors; MTT, methotrexate; TNF, tumor necrosis factor; UC, ulcerative colitis.